

9. A substantially pure polypeptide comprising the amino acid sequence of SEQ ID
A1 NO:4.

10. A polypeptide comprising the amino acid sequence encoded by SEQ ID NO:3.

18. A polypeptide comprising an antigenic fragment of the polypeptide of claim 9,
A2 wherein said fragment is at least 10 residues in length and wherein said fragment lacks a
transmembrane domain.

19. A substantially pure polypeptide comprising a fragment of a sequence of a naturally-
occurring platelet activation polypeptide, wherein said sequence is SEQ ID NO:4 and wherein
said polypeptide binds to MAb 3B2 (ATCC Designation No. CRL-11986).

22. The polypeptide of claim 18, wherein said fragment is at least 20 residues in length.

23. The polypeptide of claim 18, wherein said fragment is at least at least 50 residues in
A3 length.

24. The polypeptide of claim 18, wherein said fragment is at least at least 60 residues in
length.

25. The polypeptide of claim 18, wherein said fragment is at least at least 100 residues in
length.

26. The polypeptide of claim 18, wherein said fragment is at least at least 200 residues in

length.

27. The polypeptide of claim 18, wherein said fragment is at least at least 300 residues in length.

28. The polypeptide of claim 19, wherein said fragment is at least 20 residues in length.

29. The polypeptide of claim 19, wherein said fragment is at least at least 50 residues in length.

30. The polypeptide of claim 19, wherein said fragment is at least at least 60 residues in length.

31. The polypeptide of claim 19, wherein said fragment is at least at least 100 residues in length.

32. The polypeptide of claim 19, wherein said fragment is at least at least 200 residues in length.

33. The polypeptide of claim 19, wherein said fragment is at least at least 300 residues in length.

AG
concl.